Validity of Prostate Health Index and Percentage of [-2] Pro-Prostate-Specific Antigen as Novel Biomarkers in the Diagnosis of Prostate Cancer: Omani Tertiary Hospitals Experience

Saidi, S.; Riyami, Nafila B. Al; Marhoon, Mohammed S. Al; Saraf, Mohammed S. Al; Busaidi, Salim S. Al; Bayoumi, Riad; Mula-Abed, Waad Allah

doi:10.5001/omj.2017.55

Cited by 11 publications

(5 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When we used a threshold value of 1.66 for %p2PSA, 25 it had a sensitivity of 94.2% and a specificity of 62.5% with NPV of 71.4% and PPV of 91.5%. The AUC for %p2PSA is shown in Fig.…”

Section: Resultsmentioning

confidence: 99%

Utility of Prostate-Specific Antigen Isoforms and Prostate Health Index in the Diagnosis of Metastatic Prostate Cancer

2022

View full text Add to dashboard Cite

Objective The current study was undertaken to investigate the utility of total prostate-specific antigen (tPSA), its isoform [-2] proPSA (p2PSA), and prostate health index (PHI) in the diagnosis of metastatic prostate cancer (PCa). Materials and Methods This study was conducted from March 2016 to May 2019. Eighty-five subjects who were diagnosed with PCa for the first time, following transrectal ultrasound-guided prostate biopsy, were included in the study. The prebiopsy blood samples were analyzed in Beckman Coulter Access-2 Immunoanalyzer for tPSA, p2PSA, and free PSA (fPSA), and the calculated parameters included %p2PSA, %fPSA, and PHI. Mann–Whitney's U test was used as test of significance, and p-value less than 0.05 was considered statistically significant. Results Of the 85 participants, 81.2% (n = 69) had evidence of metastasis, both clinically and pathologically. The median tPSA (ng/mL), p2PSA (pg/mL), %p2PSA, and PHI were significantly higher in the group with evidence of metastasis (46.5 vs. 13.76; 198.0 vs. 35.72; 3.25 vs. 1.51; 237.58 vs. 59.74, respectively). The sensitivity (%), specificity (%), negative predictive value (%), and positive predictive value (%) to diagnose metastatic PCa of tPSA at a cutoff of 20 ng/mL, PHI at a cutoff of 55, and %p2PSA at a cutoff of 1.66 were 92.7, 98.5, and 94.2; 37.5, 43.7, and 62.5; 54.5, 87.5, and 71.4; and 86.4, 88.3, and 91.5, respectively. Conclusion Using tests such as %p2PSA and PHI in the standard armamentarium for the diagnosis of metastatic PCa in addition to PSA will help in selecting the appropriate treatment strategy, including active surveillance.

show abstract

“…When we used a threshold value of 1.66 for %p2PSA, 25 it had a sensitivity of 94.2% and a specificity of 62.5% with NPV of 71.4% and PPV of 91.5%. The AUC for %p2PSA is shown in Fig.…”

Section: Resultsmentioning

confidence: 99%

Utility of Prostate-Specific Antigen Isoforms and Prostate Health Index in the Diagnosis of Metastatic Prostate Cancer

2022

View full text Add to dashboard Cite

show abstract

“…Additionally, PHI (total PSA, free‐PSA, p2PSA isoform), 4KScore (total PSA, free‐PSA, intact PSA, hK2), fusion between the transmembrane serine protease gene (TMPRSS2), and the v‐ets erythroblastosis virus E26 oncogene (ERG) (TMPRSS2‐ERG) are amongst the best known diagnostic biomarkers/scoring methods that have been developed relatively recently for PCa detection 59 . The SE and SP for these biomarkers/scoring methods range from 0.75 to 0.93, and 0.33 to 0.80, respectively 60–63 . Besides, a number of studies have assessed the potential of circulating miRNAs as early‐stage, localized prostate cancer biomarkers 64,65 .…”

Section: Discussionmentioning

confidence: 99%

“…59 The SE and SP for these biomarkers/scoring methods range from 0.75 to 0.93, and 0.33 to 0.80, respectively. [60][61][62][63] Besides, a number of studies have assessed the potential of circulating miRNAs as early-stage, localized prostate cancer biomarkers. 64,65 Moltzahn et al have shown that miR-106a and miR-1274 possessed an AUC of 0.928.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of cell‐free DNA accuracy as diagnostic biomarker for prostate cancer: A systematic review and meta‐analysis

Chen

Sadeghi

2021

Biotech and App Biochem

View full text Add to dashboard Cite

This updated meta-analysis aimed to assess the diagnostic performance of circulating cell-free DNA (cf-DNA) for prostate cancer (PCa). Methods: A systematic search was conducted in PubMed, Scopus, Web of Science, and Embase databases to retrieve related studies. Several diagnostic estimates, including sensitivity (SE), specificity (SP), likelihood ratios (LRs), and diagnostic odds ratio (DOR) were also used to perform the meta-synthesis. Additionally, the area under hierarchical summary receiver operating characteristic curves (AU-HSROC) was used as a global measure of test accuracy. Results: Twenty-nine unique articles were enrolled in the meta-analysis. Pooled SE and SP for overall accuracy of cf-DNA in PCa were obtained as 0.54 (95% CI: 0.47-0.61) and 0.92 (95% CI: 0.88-0.95), respectively. Positive LR (PLR) was 6.8 (95% CI: 4.9-9.5, I 2 : 92.98%) and negative LR (NLR) was 0.5 (95% CI: 0.43-0.58).Pooled DOR was 13.56 (95% CI: 9.49-19.37) and the AU-HSROC was 0.83 (95% CI: 0.79-0.86). Conclusion:The present study suggested that cf-DNA assays have comparable SE as well as remarkably higher SP (qualitative assays) than common biomarkers in the detection of PCa like prostate-specific antigen (PSA). In addition, cf-DNA assays have better performance in PCa confirmation and almost similar performance to PSA in excluding PCa patients.

show abstract

“…PHI (prostate health index) is serum based biomarker it is a strongest biomarker. When compare to other biomarker PHI has high specificity and sensitivity which use to avoid unnecessary biopsies [14]. TNF-α, sTNFR1 and IL-8 was measured in the serum sample using ELSIA kit, it gives highly significant detection of prostate cancer in men compare to PSA [15].…”

Section: Prostate Cancer Current Diagnosismentioning

confidence: 99%

Role of Nanotrace Element in Prostate Cancer an Update

Jenifer, S.E.,

Rainy, J.W,

Velmurugan

2023

JCTI

View full text Add to dashboard Cite

Recently, nanomedicine has had a great impact on drug discovery and made the way for the drug delivery system for therapeutic utility. There are many nanoscale products increasing in the research field and in the medical sector. Nanoparticle modified drugs are being developed and brought into the market for the treatment of cancer. The nanoparticle drug carrier can improve the stability of the drug by decreasing the cancerous cell and involving the drug at disease site. Essential trace elements are mostly important for the physiological and biochemical aspects in the human system. Nowadays nanotrace elements are used for the treatment of prostate cancer. In this review the venture and exploration of application of nanomedicine and the use of nanoparticles with essential trace elements will give a wide range of benefits for the treatment for prostate cancer.

show abstract

Validity of Prostate Health Index and Percentage of [-2] Pro-Prostate-Specific Antigen as Novel Biomarkers in the Diagnosis of Prostate Cancer: Omani Tertiary Hospitals Experience

Cited by 11 publications

References 17 publications

Utility of Prostate-Specific Antigen Isoforms and Prostate Health Index in the Diagnosis of Metastatic Prostate Cancer

Utility of Prostate-Specific Antigen Isoforms and Prostate Health Index in the Diagnosis of Metastatic Prostate Cancer

Evaluation of cell‐free DNA accuracy as diagnostic biomarker for prostate cancer: A systematic review and meta‐analysis

Role of Nanotrace Element in Prostate Cancer an Update

Contact Info

Product

Resources

About